Pfizer buys into PD-1/VEGF competition with 3SBio deal
Pfizer will pay China’s 3SBio $1.25 billion upfront to gain access to a cancer therapy that could rival Akeso and Summit’s closely watched immunotherapy ivonescimab.
Pfizer will pay China’s 3SBio $1.25 billion upfront to gain access to a cancer therapy that could rival Akeso and Summit’s closely watched immunotherapy ivonescimab.
